Immunovant, Inc. (IMVT) stock
Close on Nov 11, 2026Market cap $7.65BP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $7.65B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 11.65
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$508.96M
- EPS, diluted
- -$2.56
- Free cash flow
- -$407.32M
- Book value per share
- $3.18
- Diluted shares
- 207M
Trading
- Next earnings
- Feb 5, 2027 (estimated, before the open)
- Previous close
- $35.71
- Open
- $35.77
- Day's range
- $35.52 – $37.59
- Volume
- 1,712,167
- Average volume (20 days)
- 1,501,222
- Index membership
- Russell 2000 (since Jun 2020), Russell 3000 (since Aug 2020)
- Beta (5 years)
- 1.11
- 52-week range
- $21.86 – $45.42
- RSI (14 days)
- 70.5
- Volatility (1 year)
- 58.3%
- Relative volume
- 1.30×
- WACC
- 10.5%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2019, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | IMVT | S&P 500 | Difference | IMVT per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +21.6% | -2.4% | +24.0 pts | ||
| 3 months | -9.5% | -1.2% | −8.4 pts | ||
| Year to date | +45.7% | +12.3% | +33.4 pts | ||
| 1 year | +61.8% | +12.4% | +49.4 pts | ||
| 3 years | +13.5% | +78.8% | −65.3 pts | +4.3% | +21.4% |
| 5 years | +337.3% | +75.2% | +262.1 pts | +34.3% | +11.9% |
Nine years at a glance
Fiscal years 2018 to 2026 and trailing twelve months, USD
Net income
EPS, diluted
Free cash flow
Press releases
Releases Immunovant filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Update
About Immunovant
Biological Products, (No Diagnostic Substances)
Immunovant, Inc. is a clinical-stage immunology company focused on developing targeted treatments for individuals suffering from autoimmune disorders. Its lead candidate is IMVT-1402 (imeroprubart), a fully human monoclonal antibody designed to inhibit the neonatal fragment crystallizable receptor (FcRn) and lower levels of pathogenic immunoglobulin G antibodies. The company develops treatments intended for subcutaneous delivery via an autoinjector across multiple disease areas, including endocrinology, rheumatology, neurology, and dermatology. Its prospective customer and patient base includes individuals affected by conditions such as Graves' disease, difficult-to-treat rheumatoid arthritis, cutaneous lupus erythematosus, and Sjögren's disease.
Company profile, executives and historyImmunovant stock: common questions
What is Immunovant's stock price?
IMVT closed at $37.04 on Nov 11, 2026, up 3.72% on the day. Over the past 52 weeks it traded between $21.86 and $45.42.
What is Immunovant's market cap?
Immunovant was worth $7.65B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is IMVT's P/E ratio?
Immunovant lost money over the twelve months to Sep 30, 2026 (diluted EPS -$2.56), so it has no meaningful P/E ratio.
Does Immunovant pay a dividend?
No. Immunovant has not paid a cash dividend over the last twelve months.
When does Immunovant report earnings next?
Immunovant is expected to report Q3 FY2027 results on Feb 5, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has IMVT stock performed over the past year?
Including dividends, IMVT returned +61.8% over the past year, against +12.4% for the S&P 500.
How many IMVT shares are sold short?
19M shares were sold short at the latest FINRA report, 21.07% of the float, or 15.3 days of average trading volume.
Who are Immunovant's competitors?
Companies most similar to Immunovant by business, industry and size include IMA, SABS, ZURA, CABA, ARTV.
See a number that looks wrong?